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Ethical Health Technology Assessment in Latin America: Lessons 
from Canada and Argentina
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Abstract: A wide array of biomedical and genetic technologies is becoming available in both developed and developing na-
tions. µis situation is the cause of growing concern for health policy makers who must evaluate the utility of these technolo-
gies for their inclusion in public health insurance programs. Ideally, policy makers would have the information necessary to 
rationally allocate scarce resources, prioritise technologies, and ensure fair access to necessary health care services. µe reality, 
however, is that policy makers often do not have such information. In this paper, we argue that the ﬁeld of Health Technology 
Assessment (HTA), through the integration of ethical analyses (i.e., an “ethical HTA”), can enable Argentinean and other 
Latin American policy makers to better understand the soco-ethical concerns raised by new biotechnologies.
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Evaluación ética de la tecnología en salud de Latinoamérica: lecciones aprendidas de Canadá y 
Argentina
Resumen: Una amplia gama de tecnologías biomédicas y genéticas ya se encuentra disponible tanto en los países desar-
rollados como en vías de desarrollo. De allí la importancia de evaluar dichas tecnologías para su ulterior inclusión en los 
programas de salud pública. Idealmente, los responsables de formular políticas dispondrían de la información necesaria para 
asignar los escasos recursos de manera racional, priorizar tecnologías y asegurar un acceso equitativo a los servicios de salud. 
Sin embargo, la realidad es que los responsables de formular políticas carecen a menudo de dicha información. En este trabajo 
argumentamos que la evaluación ética de tecnologías sanitarias permitiría a los decisores políticos argentinos y de otros países 
latinoamericanos comprender mejor las inquietudes socio-éticas que las nuevas biotecnologías plantean.
Palabras clave: evaluación tecnologías sanitarias, bioética, política, genética, pruebas prenatales, Argentina, Canadá
Avaliação Ética da Tecnologia em Saúde na América Latina: Lições aprendidas do Canadá e Ar-
gentina
Resumo: Foi disponibilizada uma ampla coleção de tecnologias biomédicas e genéticas tanto em países desenvolvidos como 
nos países em desenvolvimento. Esta situação é a causa de preocupação crescente dos formuladores de políticas públicas de 
saúde sobre como avaliar a utilidade destas tecnologias para a sua inclusão em programas de saúde pública. Idealmente, os 
formuladores de políticas públicas deveriam ter a informação necessária para distribuir racionalmente os escassos recursos, 
priorizar tecnologias e garantir acesso justo aos serviços de cuidado à saúde necessários. A realidade, entretanto, é que os 
formuladores de políticas públicas em geral não têm tal informação. Neste artigo, argumentamos que o campo da avaliação 
de tecnologia de saúde (ATS), através da integração de análise ética (ex., uma “ATS ética”), pode capacitar os formuladores 
de políticas públicas da Argentina e de outros países latino-americanos, a entender melhor as preocupações sociais éticas 
producidas pelas novas biotecnologias.
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Introduction
µe introduction of new biotechnologies in any 
health care system is a complex process that is 
closely tied to economic, political and cultural 
factors and thus poses a host of challenging so-
cial and ethical issues in need of urgent attention 
by policy makers. One approach that has been 
used (with some success) in developed countries 
to evaluate new and potentially contentious tech-
nologies for integration into health care systems, 
is the application of Health Technology Assess-
ment (HTA) processes(1-3). HTA can be deﬁned 
as “the scientiﬁc evaluation of medical technolo-
gies regarding their eﬀectiveness, appropriateness, 
eﬃciency as well as social and ethical aspects and 
implications” (Swiss Network of HTA 2010)4. 
One of the aims of HTA is to provide the broad 
range of empirical and social information neces-
sary for policy makers to make well founded deci-
sions about the integration of new technologies 
into health programs.
In Latin America, and for our purposes Argen-
tina, the production of HTA analyses is still quite 
limited. However, in March 2002, the Ministry 
of Health recognised the importance of HTA and 
announced that it would be necessary to imple-
ment a formal process of technology evaluation 
in order to help rationalise decisions about health 
care funding and delivery (República Argentina, 
Decreto no. 674/2003)5. In a context, such as 
Latin America, where poverty and social exclu-
sion aﬀect millions of people, the result is signiﬁ-
cant inequalities in access to health services and 
technologies. As such, HTA of new health tech-
nologies must be extended beyond cost-beneﬁt 
analyses, to also include the evaluation of issues 
relating to fair and inclusive access to services, 
and the design of more just health and social poli-
cies. But producing an “ethical HTA” requires – 
amongst other things (e.g., a clear framework and 
methodology, empirical evidence, capacity build-
ing and public policies) – knowledge and exper-
tise in ethical analysis that is not often available in 
HTA agencies, in either developed or developing 
countries. 
4 For more information see the Swiss Network of HTA available at: 
http://www.snhta.ch/   
5 República Argentina. 2003. Resolución Ministerial no. 674/2003. 
Programa Médico Obligatorio y Evaluación de Tecnologías Sanitar-
ias”, edited by Superintendencia de seguros de la Nación. Buenos Ai-
res: República Argentina (http://www.sssalud.gov.ar)
µere are, however, some models of how ethics 
can be integrated into HTA processes. To illus-
trate key elements necessary for eﬀectively inte-
grating ethics and HTA in Argentina, we present 
the case of the Agence d’Évaluation de Technolo-
gies et de Modes d’Intervention en Santé (AET-
MIS) in Québec, Canada, as an example of how 
HTA agencies can work to more actively integrate 
ethical analyses into its HTA processes. Building 
on this example, we argue for the importance 
of conducting “ethical HTA” in Argentina that 
speciﬁcally includes considerations of equity, and 
focuses not simply on eﬃcacy or eﬃciency. We 
further argue that local professionals trained in 
bioethics are legitimate and vital sources of ad-
vice on ethics matters, and can contribute both 
to the development of more fully informed HTA 
recommendations (e.g., about consequences of 
adopting a given technology), and to the develop-
ment of greater public transparency in the policy 
arena.
 
History & Development of HTA
Prior to the systematic use of HTA, policy mak-
ers lacked the technical knowledge and tools 
to analyse the consequences of implementing 
new technologies such as computerized tomog-
raphy scanner, or diverse predictive or diagnos-
tic tests(4). In 1974, the U.S. Senate requested 
the Oﬃce of Technology Assessment (OTA) to 
study the justiﬁcations for North American hos-
pitals implementing expensive health technolo-
gies and procedures6. µe result of this inquiry 
was the production of a series of reports and the 
development of an innovative tool for the analysis 
of health policies(4). Since the 1980’s, the interest 
manifested by diﬀerent stakeholders (e.g., health 
care managers, the pharmaceutical industry, aca-
demics, patient associations, and policy-makers) 
for HTA has grown considerably, especially in the 
developed nations. µe rapid deployment of new 
health technologies, their increasing costs in the 
context of limited health care budgets, and the 
uncertainty provoked by as yet unknown eﬀects 
are just some of the reasons that have contributed 
to this interest in HTA(2,3,5).
6 For a detailed discussion of the origins and development of HTA and 
the creation of the OTA, see for example the National Information 
Center on Health Services Research and Health Care Technology, 
available at: http://www.nlm.nih.gov/nichsr/hta101/ta10103.html
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By mid-1990, the USA, Canada and most west-
ern European countries had implemented diverse 
health technology evaluation systems through the 
creation of public and/or private agencies (e.g., 
ministerial commissions, non-governmental or-
ganisations, university research teams). µese 
groups were given the mandate to evaluate the se-
curity, eﬃcacy and cost-eﬀectiveness of new bio-
medical technologies, but also to reﬂect on their 
economic, legal and socio-ethical implications; in 
practice, however, socio-ethical analysis has been 
and are still rarely performed(6).
International HTA groups were also created, most 
notably the International Society of Technology 
Assessment in Health Care (now called Health 
Technology Assessment International, HTAi) and 
the International Network of Agencies for Health 
Technology Assessment (INAHTA), established 
in 1993 and currently including members from 
more than 50 national HTA agencies.
Although the majority of HTA is performed in 
order to assess speciﬁc technologies, it can also be 
used as an approach to evaluate the performance 
of health care systems and services. For example, 
some Canadian provinces (notably Québec, On-
tario and British Columbia) have implemented 
initiatives to reorganise services in order to re-
spond more eﬃciently to their populations’ health 
needs. In Canada, the restructuring of health 
care systems has in part been necessitated by the 
“aging population, rapid development of medical 
technologies and increasing costs”(7:1464).
In Latin America, however, HTA processes are 
much less well developed and HTA agencies are 
still few in number. In 1998, the Pan American 
Health Organization (PAHO) conducted a study 
with the aim of determining the situation of 
HTA in “the Americas”. µis study identiﬁed two 
major pitfalls for Latin American nations seeking 
to implement technology evaluation procedures: 
1) the “misunderstanding” of decision-makers 
about the importance of HTA for the health care 
systems, and 2) the absence of specialised staﬀ(2). 
µis study also determined that, as a consequence 
of the lack of evaluations, countries in Latin 
America were incorporating new health technolo-
gies into their health care systems without taking 
into account their own regional particularities, 
giving as a result “a diﬀusion of  sophisticated 
technologies” which are almost unrelated to the 
populations’ needs(2).
In Argentina, until 2000, decision makers did 
not recognise HTA as a tool that could help with 
the rational allocation of resources(8). However 
following the severe economic crisis that aﬀected 
the country in 2001, the demand for HTA has 
been growing considerably as well as its role in the 
decision-making process(9). Argentinean policy 
makers have noted that a formal process of tech-
nology evaluation can contribute to transparency 
and eﬃciency in health policy decision-making 
processes (República Argentina 2003). Decision 
makers are now more aware of the relevance of 
HTA and this encourage the development of lo-
cal HTA processes(9).
In 2008, the Health Ministry created the Co-
misión Nacional Salud, Ciencia y Tecnologia (to 
replace the former Comiisón Nacional Salud In-
vestiga) with, as one its aims, the institutional-
ization of HTA in the health care system and the 
promotion of scientiﬁc evidence in health policy 
decision making7. An HTA working group was 
created within this body in 2009; to date, the 
evaluations performed by consist primarily of lit-
erature reviews and consultation with experts, and 
the resulting short reports focus primarily on eco-
nomic information, e.g., about cost-eﬀectiveness. 
µese technical reports, albeit very helpful, pro-
vide decision makers with only partial informa-
tion about speciﬁc aspects of technologies, such 
as costs and eﬃcacy, which is arguably insuﬃcient 
to enable the development of comprehensive and 
eﬀective health policies. 
One point that deserves particular attention is the 
fact that technical reports usually lacks of formal 
recommendations about whether to include a 
technology in the health care system. Such rec-
ommendations would arguably not be possible 
(or at least not very helpful) if the primary an-
alyses do not also integrate attention to social, 
ethical and political factors that go beyond issues 
of cost-eﬀectiveness. µe problem with such a 
7 See: República Argentina, Ministerio de Salud y Ambiente. Comisión 
Nacional Salud, Ciencia y Tecnología. Later, in 2009, the “Unidad Co-
ordinadora de Evaluación y Ejecución de Tecnologías en Salud” was 
created within the Secretary of Policies, Regulations and Institutions 
by Ministerial Resolution 458.
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lack of formal recommendations is that it cre-
ates uncertainty and ambiguity for the various 
actors involved (e.g., patients, physicians, health 
managers, policy makers); without clear guid-
ance, these actors will be hard pressed to make 
well informed decisions (e.g., about whether to 
use and/or pay for a procedure) in what are often 
very delicate situations.
µe aforementioned awareness that decision 
makers currently show in Argentina about the 
important of HTA is a very positive step in the 
right direction. Yet as will be explained below, 
the systematised production of contextualised 
studies and formal integration of ethical issues in 
HTA is still missing in Argentina, as well as in the 
rest of the Latin American nations. Nevertheless, 
there is an opportunity for local HTA producers 
to broaden the scope of their evaluations. HTA 
is becoming both a professional practice and an 
academic discipline in some regional countries, 
such as Argentina (e.g., the work conducted by 
the IECS agency)8; and with a developing and 
vibrant bioethics community, there is also the 
possibility to integrate ethical expertise so as to 
build an ethical HTA that can help policy an-
alyses and decision making, as is increasingly the 
case in North American and European nations. 
A Place for Ethics in Health Technology As-
sessment?
Following Blanquaert & Caron(10) the process 
of HTA can be described as a combination of 
two phases: 1) assessment, which includes epi-
demiological studies, the collection of all avail-
able scientiﬁc information (e.g., literature review, 
cost-eﬀectiveness analyses) and then a subsequent 
analysis and synthesis; and 2) appraisal, in which 
contextualised studies are conducted and recom-
mendations made. As Blancquaert(11) explains, 
contextual analyses that are broader or more 
comprehensive than the standard or traditional 
assessments are needed in order to produce clear 
8 IECS is the only Argentinean institution (and one of only a few in 
Latin America) aﬃliated with the international network INAHTA. 
As such, the IECS is directly linked with the international HTA com-
munity, which facilitate the exchange of ideas, methodologies and 
reporting models that could be adapted to the local context. µis 
relationship provides precious opportunities for collaboration and 
shared learning to help improve and enlarge the production of HTA 
in Argentina.
and pertinent recommendations adjusted to local 
realities. Speciﬁcally, appraisal takes into account 
the environment in which a technology emerges 
and the diﬀerent positions of the various stake-
holders concerned by the use of such a technol-
ogy(11). 
Despite the recognition in the HTA community 
of the need for broader evaluations that include 
socio-ethical analyses, the aforementioned ap-
praisal phase is not yet performed in a system-
atized manner by most HTA agencies. µis gap 
between HTA mandate and practice has been 
highlighted by both HTA producers and bio-
ethics scholars(6). Even when HTA producers 
recognise the importance of and need to address 
socio-ethical concerns, it has often proven diﬃ-
cult to conduct and integrate ethical analyses be-
cause of a lack of specialised staﬀ and economic 
resources to assess, in a timely manner, all aspects 
of a technology(12,13).
In addition, as noted by Lehoux and Williams-
Jones(6), the absence of adequate frameworks 
and procedures to guide such ethical analyses fur-
ther complicates the situation. As a result, the for-
mal integration of socio-ethical analyses is mostly 
conducted by “ad-hoc” advisory groups(14), even 
in jurisdictions where HTA has been practiced 
for many years. It should not be surprising, then, 
that if integrating socio-ethical analyses into HTA 
is diﬃcult in North American and Europe, the 
situation will be even more challenging in coun-
tries, such as those in Latin America, in which 
this multidisciplinary ﬁeld of study is still in its 
earliest stages of development. Nonetheless, there 
are some models for integrating ethical analyses 
into HTA processes(1,13,15,16) that are worth 
attention, and could be eventually adapted or 
modiﬁed to the diﬀerent social contexts of Latin 
American countries.
 
µe Québec Experience: AETMIS
One of the few HTA agencies in Canada that had 
attempted to integrate ethical analyses into its 
practices was the Agence d’évaluation des tech-
nologies et des modes d’intervention en santé 
(AETMIS), in the province of Québec. Created 
in 2000, AETMIS was an independent organi-
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of prenatal screening for Down syndrome during 
the ﬁrst-trimester. After evaluating diverse par-
ameters, the report concluded that even while the 
screening modalities were eﬀective, more research 
was still needed before implementing “wide-scale 
ﬁrst-trimester screening in Québec”(18). In Janu-
ary 2009, the Québec Commissaire à la santé et 
au bien-être (MSSS) published a report that built 
on the AETMIS evaluation and, in light of new 
technological developments and changes in the 
social context, recommend the introduction of 
population screening for Down Syndrome. µe 
important point to note is that in both cases, 
the social and ethical concerns related to Down 
Syndrome (e.g., issues of stigmatisation, access to 
services for a vulnerable population, equity in ac-
cess to prenatal screening) where considered and 
integrated in the analyses and the broader policy 
making process.
µe changes in medical practices engendered by 
the development of new biomedical technolo-
gies made it necessary for AETMIS to expand 
the traditional process of HTA to include assess-
ment and appraisal processes; but they have also 
continued to examine and test diﬀerent meth-
ods (e.g., working across diverse interest groups 
and stakeholders) with which to integrate ethics 
into HTA. To be clear, we are not suggesting that 
AETMIS is the ideal or perfect model for ethical 
HTA; instead, we argue that AETMIS is a helpful 
example or case study from which other agencies 
and countries can learn to support their own ef-
forts to integrate ethics into HTA processes. To 
see how some of these lessons might be applied 
in the Argentinean context, we turn now to an 
examination of an ethical HTA for the case of 
prenatal genetic testing.
 
An Ethical HTA in Argentina: µe Example of 
Prenatal Genetics Testing
To better illustrate the need to expand HTA pro-
cesses in Argentina (and Latin America more gen-
erally) to include ethical analyses, we present here 
the case of prenatal genetic testing (PGT), a class 
of health technology that raises numerous social 
and ethical concerns that should be assessed, 
alongside clinical and economic considerations.
sation linked to the Ministère de la santé et des 
services sociaux (MSSS, Ministry of Health and 
Social Services of Québec). µe AETMIS re-
cently merged with the Conseil du médicament 
(committee in charge of evaluating medications 
for inclusion in the Quebec public health insur-
ance program), and in January 2011 became the 
Institut national d’excellence en santé et en servi-
ces sociaux (INESSS); its future operating prac-
tices and the place for ethical analyses are as yet 
unknown, so for this paper we will focus on the 
practices of the AETMIS. 
µe goal of AETMIS was to support and counsel 
health decision makers in the Québec govern-
ment in their development of health policy. AET-
MIS was strongly engaged in promoting evalua-
tion, knowledge translation, teaching and other 
educational activities(17), similar to other HTA 
agencies in Canada and internationally. AETMIS 
performed comprehensive analyses (assessment 
and appraisal), that can include, for example, the 
use of statistics and other scientiﬁc or health in-
formation about the Québec population(11).
µe ethical implications of a technology are ana-
lysed within Québec’s socio-cultural, economic 
and political context. Diﬀerent methods are em-
ployed to achieve this integration: for instance, 
focus groups may be organised with stakehold-
ers or interviews conducted with diﬀerent actors 
concerned by a given technology, depending on 
the particular circumstances of each evaluation. 
At this point, it is necessary to recognize the 
strong inﬂuence exerted by the various stakehold-
ers involved in implementing such innovations in 
a given context (e.g., technology designers, health 
administrators, physicians, patient groups) as well 
as the existence of diverse perceptions, interests 
and expectations that each may have about the 
same technology. Considering these factors and 
integrating them as part of the HTA process al-
lows the AETMIS evaluators to obtain more ac-
curate information about the utility, feasibility 
and acceptability of a technology in the Québec 
context.
Each HTA report produced formulates pragmatic 
policy “recommendations directly applicable to 
the Québec health care system”(17). For example, 
in 2003, AETMIS produced a report about the use 
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ﬁciency, the equity and quality and of the health 
policies. µis situation is made worse by the fact 
that in Argentina, the links between the scientiﬁc 
and political spheres have been historically quite 
weak, which reduces the transparency of how 
policies are built. Regardless of the lack of regu-
latory oversight, Argentina, as with other neigh-
bouring countries like Chile and Brazil, is rapidly 
incorporating new biomedical technologies such 
as molecular genetic tests (primarily into the pri-
vate health sub-sector) that have been developed 
in North America and Europe(3,25); but this in-
tegration happens without appraisal of the social 
or political contexts relevant to their introduc-
tion. Such practices can result in a waste of lim-
ited resources, the use of possibly inappropriate 
technologies, and the perpetuation of a situation 
where populations have critical but unmet med-
ical or public health needs; this creates inequity in 
access to important health care services and con-
tributes to broader social injustice.
µe tendency to adopt health technologies with-
out detailed analysis is probably to some extent 
rooted in a widespread public belief in the power 
of high technologies to solve health problems 
(also maybe encouraged by the private healthcare 
sector), and a perception by many people (includ-
ing policy makers and the general public) that 
access to these technologies is synonymous with 
being at the vanguard of modern medicine. As 
Lehoux(26) states, “for several observers, health 
technology…cannot be (irrationally) resisted”, 
because “technology sounds modern… must be 
about the latest. It is also supposed to be better. 
But how and when do we know that an innova-
tion is better?”(26:xii-3). µe absence of context-
ualised assessments and integrated appraisals im-
pedes eﬀorts to determine if prenatal genetic tests 
or other biomedical technologies are appropriate 
or not for the Argentinean society. 
To produce contextualised studies, it is obvious 
that substantial human and material resources are 
needed(7); but so to is awareness on the part of 
HTA producers of the importance of enlarging 
their studies beyond the analysis of clinical and 
economic considerations, to also include ethical 
and social issues, in order to make more accurate 
and pertinent recommendations. Unfortunately, 
chronic understaﬃng and a lack of suﬃcient ﬁ-
In Argentina, the medical application for PGT in 
the public health care and social security system9 
is still quite limited, nor are there well developed 
public policies or regulations governing the use 
of these technologies(19,20). Nonetheless, pri-
vate access to such services and other reproduct-
ive technologies is relatively easy (through private 
clinics) and Argentinean professionals employ the 
same techniques as their colleagues in developed 
countries(20,21)10. µis shows that there is at 
least some degree of acceptability of these tech-
nologies by the Argentinean public, and by health 
professionals.
Following Blancquaert et al.(22), we note that as 
objects of assessment, genetic or genomic tech-
nologies are very complex, raising a considerable 
number of concerns regarding appropriateness 
and acceptance of these new technologies in di-
verse societies. Although many socio-ethical con-
cerns about PGT are shared by other branches of 
medicine (e.g., who will have access to the service, 
who will pay), some are particular to this technol-
ogy, such as the right to reproductive autonomy, 
conﬁdentiality of genetic information, and the 
potential risk of discrimination and stigmatisa-
tion. But PGT also raises questions about how 
to address diverging personal convictions, values 
and religious beliefs. In the speciﬁc case of Argen-
tina, the lack of regulations or guidelines dealing 
with genetic tests in general has made possible the 
introduction of commercial PGT, some of which 
may lack medical validation(20,23). All of these 
issues pose serious challenges for decision makers.
Probably one of the most important challenges 
for an eﬀective HTA (to inform health care poli-
cies) in Argentina with regards to PGT —or for 
health services more generally— is the fragmenta-
tion of the health care system in terms of struc-
ture and organisation of insurance coverage(24). 
Even when HTA is conducted, the absence of 
formal recommendations following these assess-
ments does not allow Argentinean policy makers 
to be fully informed about the range of context-
ual issues associated with a particular technology, 
and thus they remain unable to enhance the ef-
9 µe Argentinean health care system is formed by 3 subsystems: the 
public, the private, and the social security system. 
10 For a detailed list of genetic services and tests already available in 
Argentina, see for example Primagen Diagnósticos Genéticos avail-
able at: http://www.primagen.com.ar/diagnosticosprenatales.php  
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In practice, integrating contextualised studies and 
ethical analysis into HTA processes will require, 
amongst others, the development of strategic 
partnerships between diverse spheres: academia, 
policy and practice(11,29). In Argentina, a re-
cent report from the aforementioned Comisión 
Nacional Salud, Ciencia y Tecnología(30) shows 
that those researchers working on human gen-
etics and its clinical applications are disconnected 
from decisions about the provision of health ser-
vices. Better collaboration with the medical gen-
etics community is needed, as well as more ﬂuid 
communication between practitioners and policy 
makers, to avoid any misunderstandings. For in-
stance, in Argentina, the ﬁeld of genetics is still 
closely associated in the public mind with eugen-
ic practices, and this is arguably one of the prin-
cipal reasons why PGT has not been included in 
public services(19,30,31). Promoting education 
and dialogue among the diﬀerent stakeholders 
—including patients and health professionals— 
would help enormously to eliminate such misper-
ceptions and misinformation.
However, producing an ethical HTA requires at 
least some knowledge about bioethics, such as 
how to use and apply relevant ethical principles, 
theories of justice, or analytic frameworks. µe 
issues faced by Argentinean HTA producers are 
very challenging, and arguably go beyond the 
tools that they currently have in hand. In the next 
section, we argue that Argentina’s Bioethics com-
munity, which has developed substantially dur-
ing the last decade, can contribute in important 
ways to the production of better and more ethical 
HTA.
 
Building Local Capacity
Although there have been some initiatives in 
Argentina to evaluate socio-ethical aspects raised 
by genetic and other biomedical technologies, 
this has tended to occur without formal integra-
tion into existing HTA processes. µe aim of 
such ethical evaluations has been to examine the 
ethical, legal, and social issues (ELSI) of genetic 
technologies, as has already been done in other 
countries, most notably in the USA, Canada and 
in Western Europe. In Argentina, some National 
Universities —such as at the Universidad Nacion-
nancial resources at HTA agencies is a major part 
of the problem, although it can in some places be 
overcome by re-allocating local resources; more 
important, however, is to develop a willingness 
on the part of HTA agencies to engage in broader 
analyses. 
In Argentina – as in other developing and de-
veloped countries – the government does not 
consider genetic testing (or most new repro-
ductive technologies) as a priority for the public 
health care system(20); prenatal genetic tests are 
provided mostly by private institutions and thus 
are accessible only for the wealthiest. But there 
may be situations in which genetic tests are ap-
propriate (e.g., for people belonging to certain 
at-risk groups) and justiﬁable in relation to other 
important health needs. Yet without a compre-
hensive HTA process that takes such issues into 
consideration, policy makers will be unable to 
rationally defend their choices (e.g., whether or 
not to include PGT in public health insurance). 
We argue that important progress can be made if 
HTA producers in Argentina begin to integrate 
the aforementioned appraisal phase as a core part 
of their HTA processes. µe capacity to conduct 
such appraisal will necessitate important eﬀorts 
in education about the ethical issues related to 
health care and genetic technologies. HTA pro-
ducers should, for example, reﬂect on and assess 
the possible consequences of not considering 
sensitive issues. For example, the growing com-
mercialization of genetic tests can lead to an ear-
ly introduction into the market of services that 
physicians may not yet be prepared to handle, and 
provide information to patients and third parties 
which can have serious legal consequences, such 
as discrimination, or even malpractice suits in the 
context of “wrongful life” claims(27) similarly 
strong patent protection and resulting high costs 
may mean that some genetic tests are simply too 
expensive to be considered for inclusion in pub-
lic health insurance programs in countries like 
Argentina. It is also important to distinguish be-
tween those situations in which genetic tests are 
appropriate or needed (e.g., for people belonging 
to at-risk groups) and so justiﬁable in relation to 
other health needs; and those situations in which 
tests are introduced primarily because of com-
mercial interest(23,28).
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Scholars trained in bioethics can contribute sub-
stantially to HTA processes. µey can employ 
several approaches, both theoretical and empir-
ical(6) and may be involved in conducting both 
qualitative and quantitative research to under-
stand and measure what people feel or are con-
cerned with, regarding a given technology. For 
instance, such research would be useful in build-
ing a better understanding of the experience of 
those people undergoing PGT in Argentina. By 
referring to ethical principles (e.g., autonomy, be-
neﬁcence, justice) and identifying societal values 
(e.g., solidarity, empathy), ethical analyses can 
help to build relevant and practical frameworks 
to better analyse genetic technologies. 
Such theoretical and empirical bioethics research 
can help to clarify a technology’s social accept-
ability, appropriateness and utility within the 
Argentinean health care system. And when in-
tegrated with comprehensive HTA evaluations, 
it then becomes feasible to produce practical 
and relevant recommendations that can be used 
to make decisions on rational grounds, accord-
ing to needs and not just according to particu-
lar interests or preferences. Yet, it is critical to be 
aware of and to guard against the use of rational 
bioethics-informed arguments in the service of 
non-transparent economic and/or political ends. 
For example, government actors may ﬁnd such 
arguments useful for legitimising questionable 
practices, such as the mandatory or “strongly en-
couraged” implementation of new but possibly 
insuﬃciently tested or justiﬁed technologies (e.g., 
vaccines of HPV or N1H1, or population gen-
etic screening of newborns for conditions where 
there are no treatments) in order to “protect pub-
lic health”. 
We agree with Battista and Hodge(29) that 
building (local) capacity and knowledge trans-
fer mechanisms remain two major challenges for 
the progress of HTA in all countries. Nonethe-
less, local capacity building can be enhanced, 
for example, by encouraging and supporting 
existing academic activities, such as research in 
health services, policy and in public health(29). 
In the case of ethics expertise, it is important to 
recognise that bioethics research and education 
has grown considerably in Latin America since 
the 1990s(34-36). An opportunity exists, then, to 
al de La Plata (UNLP) and the Universidad de 
Buenos Aires (UBA)11— have begun developing 
bioethics centres and programs. For example, 
while the ﬁrst ELSI courses for law and medic-
al students were taught by invited international 
scholars, it is increasingly local bioethics scholars 
(many of whom received training abroad and par-
ticipated in other ELSI courses oﬀered in North 
America) who are now engaged in both research 
and teaching in Argentina12.
More recently, several research ethics bodies have 
been created in Argentina and begun participat-
ing in public and policy discussions about eth-
ics and genetics, such as the Comision Nacional 
en Genética Humana created by the National 
Health Ministry; also, institutions such as the 
Observatorio de Bioética (created by the Facultad 
Latinoamericana de Ciencias Sociales, FLACSO) 
are analysing and discussing socio-ethical issues 
related to the use of new health technologies. 
Even though these bodies are not themselves 
HTA agencies, their work can be helpful for HTA 
producers. Nonetheless, the integration of ethics 
with HTA and the introduction of HTA into the 
policy sphere remain major challenges, and not 
only for developing countries(32,33).
Progress can, however, be made if Argentinean 
HTA producers build links with institutions 
where technologies are analysed from an ethical 
and social perspective, as is the case with some 
public universities, ethics commissions and non-
governmental organisations. Another possibility 
is that HTA agencies could learn from the ex-
perience of AETMIS in Québec, and incorpor-
ate onto their staﬀ scholars trained in bioethics in 
order to conduct their own analyses and reports. 
Such recruitment would be an opportunity for 
HTA staﬀ to build awareness about ethics, and 
for bioethicists to recognise and better respond to 
the speciﬁc objectives and restrictions inherent in 
HTA processes(5). 
11 µe UNESCO Bioethics Chair was established at the University of 
Buenos Aires (UBA) in 1994.
12 µe ﬁrst ELSI course in Genetics, in 1998, was ﬁnanced by the U.S. 
National Institute of Health and Dartmouth College, and directed 
by Prof. Ronald Green; this allowed Prof. M. Graciela de Ortúzar to 
start the ﬁrst courses on these subjects in the Medicine and Law Fac-
ulty, in UNLP, CIF, and was followed by several research projects and 
doctoral theses. 
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beyond the strict epidemiological analyses in cur-
rent HTA processes.
µe creation of spaces that facilitate and encour-
age public participation is important, and some 
progress is already being made in Argentina. µe 
so called “Argentinean Roundtable” is a public 
forum implemented by the National Ministry of 
Health, where diﬀerent sectors of society (govern-
ment, labour associations, scientiﬁc societies, the 
Catholic Church, etc.) participated in discussions 
about various health problems and their possible 
solutions(38). µis sort of dialogue can also be 
stimulated by those in academia – an area that is 
strongly developed in Argentina – searching for 
new avenues of collaboration with governmental 
and private institutions.
 
Conclusions 
In developing countries, people often experience 
numerous diﬃculties accessing health care servi-
ces, especially for those people with the lowest in-
come(39). In this context, more inclusive health 
policies which have the potential to improve ac-
cess to essential services are necessary. To that end, 
we argue that HTA in Argentina, as well as in the 
rest of Latin America, must engage in a broader 
or contextualized assessment of new technologies, 
to include alongside assessment, the appraisal of 
socio-ethical aspects. In particular, there is real 
need to move beyond short technical HTA re-
ports and to instead also formulate pragmatic and 
socially relevant policy recommendations. 
µere is arguably no single “best model” for how 
to integrate ethics into HTA, but it is certainly 
possible to learn from the successes and failures 
of other HTA producers. Primary research is still 
necessary in Argentina in order to clarify how 
socio-ethical questions should be appraised, and 
possible methods explored. An important ﬁrst 
step should be building awareness on the part of 
HTA producers and decision makers about the 
importance of conducting comprehensive assess-
ments. Such analyses can eventually contribute 
not only to more eﬃcient technology integration 
(i.e., to produce the desired eﬀect of improved 
public health), but also to a more eﬃcient and 
equitable organisation of the health care system 
bring together the bioethics, health research and 
HTA communities to discuss how to eﬀectively 
integrate ethical reﬂection into HTA and policy 
making. 
A promising strategy would be to start with a 
small scale pilot project at a public or private in-
stitution in which bioethicists are employed, to 
develop the aforementioned appraisal phase of 
the HTA process, for a particular health tech-
nology. For example, bioethics and social sci-
ence scholars could help gather the necessary 
social and scientiﬁc information about PGT in 
Argentina, consult with key stakeholders (e.g., 
physicians working in hospitals in which PGT is 
provided, to document existing selection criter-
ion, if any), conduct focus groups with patients 
in need of PGT to learn about their concerns, or 
survey genetics laboratories to learn what kinds of 
tests are in most demand. As seen in our example 
of AETMIS, the dissemination of study ﬁndings 
is an integral part of the HTA process; so in the 
context of the proposed pilot study, presenting 
research results in academic, public and policy 
forums could be a way to move the issue of PGT 
onto the political agenda in Argentina. 
With regards to knowledge transfer, the com-
munication and diﬀusion of HTA results and its 
translation into policy and practice needs to be 
enhanced in Argentina. As Battista and Hodge 
explain, these results are currently addressed al-
most exclusively to health ministers, but industry, 
clinicians and the public more generally should 
also be receptors of such information(29). Part-
nerships between a diversity of stakeholders are 
needed because such a translation is not just a 
“technical” or one-way (expert to user) procedure. 
Instead, evidence-based decision-making should 
be seen as an ongoing and interactive “social pro-
cess”(32). Public participation in such social pro-
cesses could be encouraged through the imple-
mentation of consultative mechanisms, as have 
been used by some European agencies (e.g., the 
“Publiforums” implemented by the Swiss Tech-
nology Assessment Agency). Such integration of 
citizens panels and other consultative mechan-
isms (e.g., roundtables) that facilitate discussions 
about the socio-ethical questions raised by new 
technologies(6,37) would go some way towards 
reﬂecting the diversity of social values, and move 
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Social inequalities are one of the core problems 
in modern health care systems, both in the de-
veloped and developing countries. According to 
Lafortune et al., equity in health and health care 
requires the “realignment” of health policies, and 
for that, “a culture of evaluation needs to be in-
fused” in the decision-making process(41:83). 
Progress to develop such a culture, can, we sug-
gest, arise through the close collaboration of 
bioethics scholars and HTA producers, with the 
shared goal of aiming to construct ethical HTA 
that can guide policy-making in more reﬂexive, 
inclusive and transparent decision making.
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in Argentina (e.g., addressing the challenges of 
understaﬃng and chronic under-funding of gen-
etic public facilities). It is essential to recognize 
that decisions based on expert analysis and advice 
can lead to better results(40), but for these results 
to be translated and accepted, they have to be in-
tegrated into broad public and policy discussions.
To address the complex social, ethical and eco-
nomic challenges raised by new biomedical 
technologies such as PGT, the development and 
collaboration between interdisciplinary teams is 
needed. We have suggested that there is room for 
the participation of local bioethics scholars who 
have to date not been involved in HTA processes. 
µese scholars can help to integrate the multiples 
perspectives of diverse stakeholders (e.g., publics, 
health professionals, corporate interests) in the 
appraisal process, and stimulate dialogue between 
the diﬀerent actors; bioethics scholars could also 
be instrumental in helping HTA producers and 
decision makers think more reﬂexively about 
issues of fairness and equity when considering 
who should have access to PGT and other novel 
and costly health technologies. Without such an 
analysis, PGT will remain a hotly contested issue 
for the Argentinean public (and only accessible 
to the wealthiest) and an ongoing challenge for 
policy makers.
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